Mindfulness for Central Serous Chorioretinopathy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKing's College Hospital NHS Trust

About this trial

The primary goal of this clinical trial is to test whether a mindfulness-based treatment is effective at shortening the duration of, and improving the features of, central serous chorioretinopathy in adults. Researchers will compare adults with central serous chorioretinopathy who undertake an 8 week mindfulness-based treatment course, with those who do no mindfulness, to see if mindfulness improves time to disease resolution and disease features.

The secondary goal of this clinical trial is to compare adults with central serous chorioretinopathy to adults with healthy eyes across a variety of stress-related factors, and also measure the change in some of these factors, if any, caused by mindfulness.

The questions this clinical trial aims to answer are:

* is mindfulness effective at improving the clinical course of central serous chorioretinopathy? * is a mindfulness-based treatment programme for central serous chorioretinopathy acceptable to adults with the disease? * if effective, does mindfulness alter any stress-related psychological or biological features in adults with central serous chorioretinopathy? * what are the stress-related psychological and biological features of adults with central serous chorioretinopathy, compared to adults with healthy eyes?

Participants will:

* Undertake daily mindfulness practices for 8 weeks and participate in fortnightly group sessions, or undertake no mindfulness * Visit the research clinic once every month for the first six months, and then again at 12 months, for checkups and tests

Eligibility criteria

Qualifiers

Adults (> 18 years old)

Active foveal centrepoint-involving CSCR

Diagnosis based on history, examination and OCT scan ± FFA

Central sub-foveal subretinal fluid on OCT scan

Disqualifiers

Any treatment for current or previous CSCR with PDT or laser

Use of any topical medication for CSCR currently, or in the last 90 days

Use of topical steroids or carbonic anhydrase inhibitors currently, or in the last 90 days

Intraocular anti-VEGF therapy in the last 180 days

Trial design

Treatments tested in this trial

  • Mindfulness

Treatment groups

100 Participants
are divided into 3 treatment groups

Sponsors and collaborators

King's College Hospital NHS Trust

Lead sponsor

King's College London

Collaborator